TOP > News Release > Corporate
2010
- 2010.02.26
- Daiichi Sankyo Group to Expand its Business Scope in Japan through Establishment of Daiichi Sankyo Espha Co., Ltd.
- 2010.02.10
- Daiichi Sankyo to Launch Innovator Products in Mexico through Ranbaxy
Companies to Fully Leverage the Synergistic Power of the Hybrid Business Model
- 2010.01.06
- Luitpold Pharmaceuticals Inc. Acquires PharmaForce, Inc., a U.S. Specialty Injectable Pharmaceutical Company
2009
- 2009.12.21
- Daiichi Sankyo to Leverage Ranbaxy's Presence in Africa for Marketing and Distribution Olmesartan to be launched in six African countries
- 2009.10.05
- Daiichi Sankyo to Leverage Ranbaxy's Presence in Mexico for Marketing and Distribution
New Division will bring Daiichi Sankyo's innovator products to Mexican market
- 2009.09.01
- Daiichi Sankyo and Ranbaxy Leverage New Business Model with Launch of EVISTA in Romania
- 2009.07.31
- DAIICHI SANKYO to Issue Stock Options (Stock Acquisition Rights) as Remuneration
- 2009.05.24
- Daiichi Sankyo and Ranbaxy Announce Reconstitution of Ranbaxy Executive Leadership
- 2009.03.31
- Ranbaxy to Launch Daiichi Sankyofs innovative antihypertensive, Olvance, in India
- 2009.02.12
- Partial Correction to Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2009
(Correction of Text and Figures)
- 2009.01.05
- DAIICHI SANKYO Records Valuation Loss, Goodwill Write-down, on Investment in Ranbaxy Laboratories
2008
- 2008.12.19
- Ranbaxy Reconstitutes Board of Directors following Strategic Alliance with Japanfs Daiichi Sankyo
Ranbaxy CEO and Managing Director Malvinder Mohan Singh Takes Additional Role as Chairman of the Board
- 2008.11.26
- DAIICHI SANKYO sets up subsidiary in Ireland
Critical step in European expansion
- 2008.11.17
- DAIICHI SANKYO Notice concerning Determination of Certain Terms of the Issue Stock Options (Stock Acquisition Rights) as Remuneration
- 2008.10.31
- DAIICHI SANKYO to Issue Stock Options (Stock Acquisition Rights) as Remuneration
- 2008.10.20
- Daiichi Sankyo and Ranbaxy Move Forward Toward
The Completion of the Landmark Deal
- 2008.07.09
- Luitpold Pharmaceuticals/American Regent and Fresenius Medical Care sign
agreements for exclusive sublicense of Venofer(R)in U.S.
- 2008.06.11
- Ranbaxy to bring in Daiichi Sankyo as Majority Partner
Strategic Combination creates Innovator and Generic Pharma Powerhouse
- 2008.03.31
- Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
- 2008.03.05
- Japanese pharmaceutical company acquires osteoporosis medication EVISTA from Lilly
DAIICHI SANKYO presses ahead with European expansion
- 2008.02.15
- DAIICHI SANKYO Notice concerning Determination of Certain Terms of the Issue Stock Options
(Stock Acquisition Rights) as Remuneration
2007
- 2007.11.30
- Share Transfer of NIPPON NYUKAZAI and SINO-JAPAN CHEMICAL
(subsidiaries of DAIICHI SANKYO)
- 2007.08.22
- Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
2006
- 2006.10.10
- Daiichi Pharmaceutical Korea to Become Wholly Owned Subsidiary of Daiichi Pharmaceutical Co., Ltd.
- 2006.08.31
- Sankyo and Ajinomoto Reach Agreement on the Development, Manufacture and Marketing of the New Diabetes Drug, AJD101
- 2006.05.26
- DAIICHI SANKYO to Amend the Articles of Incorporation
- 2006.03.30
- Announcement of Revisions to Consolidated Financial Results for the Interim Period of Fiscal 2005
(Six-Month Period Ended September 30, 2005)
- 2006.03.30
- Announcement of Revisions to Sankyo's Consolidated Financial Results for Prior Fiscal Years
- 2006.02.17
- Future Business Prospects of the Hyperlipidemia Drug Pravastatin in the United States
- 2006.01.10
- KAI Pharmaceuticals, Inc. and Sankyo Company, Limited Enter Global Alliance to Develop and Commercialize Novel Compounds for Cardiovascular Disease
2005
